Tenon Medical, Inc. (NASDAQ: TNON), a medical-device company focused on sacroiliac joint fusion, filed an amended S-1/A registering approximately 12.96 million shares — more than the company's entire current outstanding share count of roughly 11.8 million — in connection with a best-efforts public offering and related financing instruments.

Offering structure

The filing covers a $3 million best-efforts raise at a time when TNON's common stock trades near $0.60, well below Nasdaq's $1.00 minimum bid-price threshold. The offering stacks several layers of potential share issuance:

• Pre-funded warrants for approximately 4.0 million shares, exercisable at $0.001 per share. Because the exercise cost is effectively zero, these function as common-share equivalents the moment they are exercised.
• New common warrants covering roughly 6.98 million shares issued alongside the offering.
• Existing warrants for an estimated 8.2 million shares already outstanding prior to this filing.

Taken together, the fully diluted share count — including all warrants and convertible instruments — would be multiples of the current base.

Variable-rate convertible note

Among the most structurally significant features is a convertible promissory note issued with a 20% original issue discount. The note converts into common stock at 80% of the volume-weighted average price over a three-day lookback window. Critically, the conversion formula contains no floor price, meaning there is no contractual limit on how low the per-share conversion price can fall. This type of provision — sometimes described as a "death-spiral" convertible — can create a self-reinforcing dilution cycle: as the share price declines, the noteholder converts at lower prices, receives more shares, and the resulting increase in supply can push the price lower still, triggering further low-priced conversions.

The note also carries weighted-average anti-dilution protection and permits cashless exercise, both of which can accelerate share creation without generating additional cash proceeds for the company.

Nasdaq compliance

The filing explicitly contemplates a reverse stock split as a mechanism to regain compliance with Nasdaq's $1.00 minimum bid-price rule. TNON is also currently non-compliant with the exchange's $2.5 million stockholders'-equity requirement. A reverse split would consolidate share count on paper but would not, by itself, alter the economic terms of the convertible note or the outstanding warrants. Because the convertible note converts based on a percentage of market price, a reverse split would simply reset the denominator — the variable conversion formula would still track the post-split trading price at the same 20% discount.

Float mechanics

The 12.96 million shares registered in this S-1/A comprise shares underlying the pre-funded warrants, the common warrants, the convertible note, and shares issuable to the placement agent. If all registered shares enter the public float, the tradeable supply would more than double from the current base. The best-efforts structure means there is no underwriter guarantee that the full $3 million will be raised, so the actual number of shares issued will depend on investor demand at closing.

The company's dilution-risk profile rates 9 out of 10 on ShareStructure's scoring model, driven primarily by the uncapped variable-rate conversion, the absence of a price floor, and the ratio of registered shares to existing outstanding shares.